|
Imagin Medical
(CSE: IME) (OTC PINK: IMEXF)
(Frankfurt/Stuttgart Exchanges:
DPD2 )
MORE
Imagin
Medical Poised for Success
Imagin believes it will radically improve the way physicians detect
cancer and view the surgical field during minimally invasive procedures
where endoscopes are used. The initial target market is bladder cancer,
a major cancer worldwide, the sixth most prevalent in the U.S., and the
most costly cancer to treat due to a greater than 50% recurrence rate.
-
The Company has completed the development of its first prototype,
the i/Blue Imaging System. Due to its innovative optical components,
the i/Blue is expected to produce images 100 times more sensitive
than systems currently available, highlighting the cancer lesions in
less than 10 minutes compared to the current market standard of one
hour. This will make these procedures more practical, improve
outcomes and expand the market.
-
A Clinical Research study will begin after the Company receives
Internal Review Board Approval from the University of Rochester
Medical Center where Dr. Edward Messing will validate the
technology. The Company anticipates additional clinical studies over
the course of 2017 at UC Davis Medical Center, the University of
Rochester Medical Center and other institutions.
For further information, contact: Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com
About BioTechReporter.net :
BioTechReporter.net is
a subsidiary
of Target Publishing Inc, and is a leading publisher of todays market
and investment news, commentary, proprietary research and videos from
seasoned journalists, analysts and contributors covering the financial
markets and global economies. Leveraging our extensive distribution
network and social media presence, we have cultivated
a valuable audience of
engaged market enthusiasts, which in turn delivers a variety of
unique opportunities for industry partnerships, corporate
communications, market exposure and investment.
A complete disclaimer can be viewed HERE
X
|
